Clinical trial

A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer

NCT00116753

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2005-01-01

PhasePHASE2

Study timeline

Study start (unknown)2005-01-01Date precision: month

Registry last updated2010-12-10

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Interventions

DegarelixDRUG · verified · RxNorm: degarelix

Sponsors & collaborators

Ferring Pharmaceuticalslead sponsor

Mapped research locations

Saint PetersburgRussia5 BucharestRomania2 Fort MyersFlorida, United States2 TorontoOntario, Canada1 San AntonioTexas, United States1 SeattleWashington, United States1 BerlinGermany1 AuroraColorado, United States1 Kansas CityMissouri, United States1 LeuvenBelgium1 AmsterdamNetherlands1 Fort WorthTexas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00116753 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.